LightOx, based in Newcastle, has developed a UK-first solution for early-stage mouth cancers using light-activated chemotherapy. The treatment involves a gel being applied to the affected area and the drug activated with light. It is undergoing preclinical testing, is quick, simple and non-invasive with fewer side effects than surgery and significantly improves the overall patient... Read more »

The post LightOx Accelerate R&D using A4I appeared first on Lifescience Industry News.